• Explore /
  • Poster
  • / Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Afatinib in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN) harboring alterations in the HER pathway: Results of the B1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM).

Abstract Poster

Authors

null

Rachel Galot

Cliniques Universitaires Saint-Luc, Brussels, Belgium

Rachel Galot , Christophe Le Tourneau , Lisa F. Licitra , Amaury Daste , Caroline Even , Esma Saada-Bouzid , Stephanie Henry , Sylvie Rottey , Emmanuel Seront , Marie-Christine Kaminsky , Sylvie Zanetta , Annemie Rutten , Neus Baste , Philip R. Debruyne , Jérémy Leys , Konstantina Tsechilidou , Catherine Fortpied , Sandrine Marreaud , Anne-Sophie Govaerts , Jean-Pascal H. Machiels

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03088059

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 6034)

DOI

10.1200/JCO.2023.41.16_suppl.6034

Abstract #

6034

Poster Bd #

26

Abstract Disclosures

Similar Posters

First Author: Rachel Galot

First Author: Ezra E. W. Cohen

First Author: Erkut Borazanci

First Author: Hiroe Kayatani